8 completed, 5 unknown, 4 recruiting, 4 terminated. 22 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 22 | Completed 8, Unknown 5, Recruiting 4, Terminated 4, Not yet recruiting 1 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion - Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL) | Early Phase 1 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 3 | 2025-12-31 | 2025-09-17 |
| Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research Metabolically Armed CD19 CAR-T cells - Diffuse Large B-cell Lymphoma | Early Phase 1 | Recruiting | He Huang | 18 | 2023-11-16 | 2025-09-19 |
| Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Recruiting | City of Hope Medical Center | 9 | 2023-07-20 | 2026-02-04 |
| The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma anti-CD19 CAR NK cells - Diffuse Large B Cell Lymphoma | Early Phase 1 | Unknown | Changhai Hospital | 12 | 2023-03-01 | 2023-08-28 |
| Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research Metabolically Armed CD19 CAR-T cells - Diffuse Large B-cell Lymphoma | Early Phase 1 | Unknown | Anhui Provincial Hospital | 18 | 2023-02-10 | 2023-07-05 |
| A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma RD14-01 cell infusion - Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma | Early Phase 1 | Unknown | He Huang | 18 | 2022-07-05 | 2022-07-11 |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma Anti CD30 CAR-T Cell Injection - Hodgkin Lymphoma, NK/T Cell Lymphoma | Early Phase 1 | Unknown | Zhejiang University | 9 | 2022-02-10 | 2022-01-26 |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study Duvelisib, Tisagenlecleucel - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | Emory University | 4 | 2022-01-13 | 2025-01-20 |
| Imaging Apoptosis for Lymphoma Treatment Response 18F-FluorApoTrace - Diffuse Large B Cell Lymphoma | Early Phase 1 | Terminated | Washington University School of Medicine | 12 | 2021-12-06 | 2024-05-30 |
| A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma Cyclophosphamide, Daratumumab, Doxorubicin - Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma | Early Phase 1 | Recruiting | AIDS Malignancy Consortium | 15 | 2021-05-24 | 2026-10-28 |
| Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies CT125A cells, Cyclophosphamide, fludarabine - CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL) | Early Phase 1 | Unknown | Huazhong University of Science and Technology | 18 | 2021-03-01 | 2021-02-23 |
| Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma 131-I Apamistamab, CAR T-cell - B-ALL, DLBCL | Early Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2021-02-02 | 2026-02-17 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission | Early Phase 1 | Terminated | Rutgers, The State University of New Jersey | 2 | 2020-10-26 | 2023-06-26 |
| Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance Nivolumab, IV, 240 mg - Diffuse Large B Cell Lymphoma | Early Phase 1 | Completed | Fox Chase Cancer Center | 15 | 2018-05-15 | 2025-04-06 |
| Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma Pegfilgrastim, Loratadine, Placebo - Lymphoma | Early Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2015-12-14 | 2019-04-23 |
| Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Chemotherapy, Computed Tomography, Fludeoxyglucose F-18 - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 35 | 2015-10-13 | 2022-10-28 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide - Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder | Early Phase 1 | Completed | Baylor College of Medicine | 4 | 2013-01-01 | 2025-10-14 |
| Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Buparlisib, Laboratory Biomarker Analysis, Questionnaire Administration - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma | Early Phase 1 | Completed | Mayo Clinic | 7 | 2012-12-01 | 2018-10-09 |
| Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma oblimersen sodium, rituximab, cyclophosphamide - Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Early Phase 1 | Terminated | University of Nebraska | 37 | 2008-07-23 | 2023-10-24 |
Showing 20 of 22. Sign in to see all of them.
Lymphoma, Mantle-Cell (8) · Lymphoma, Follicular (7) · Burkitt Lymphoma (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Extranodal NK-T-Cell (4) · Lymphoma, Non-Hodgkin (4) · Hodgkin Disease (3) · Immunoblastic Lymphadenopathy (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Large-Cell, Anaplastic (3) · Lymphoma, T-Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Waldenstrom Macroglobulinemia (3) · Hematologic Neoplasms (2)
Hemic and Lymphatic Diseases (22) · Immune System Diseases (22) · Immunoproliferative Disorders (22) · Lymphatic Diseases (22) · Neoplasms (22) · Neoplasms by Histologic Type (22) · Lymphoproliferative Disorders (21) · Lymphoma (20) · Lymphoma, B-Cell (20) · Lymphoma, Non-Hodgkin (18) · Hematologic Diseases (5) · Leukemia, Lymphoid (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Blood Protein Disorders (4)
Cyclophosphamide (5) · Doxorubicin (3) · Etoposide (3) · Prednisone (3) · Rituximab (3) · Vincristine (3) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Immunotherapy, Adoptive (2) · Magnetic Resonance Spectroscopy (2) · Peripheral Blood Stem Cell Transplantation (2) · Biopsy (1) · Busulfan (1) · CF regimen (1) · CTL019 chimeric antigen receptor (1)
He Huang (2) · M.D. Anderson Cancer Center (2) · AIDS Malignancy Consortium (1) · Anhui Provincial Hospital (1) · Baylor College of Medicine (1) · Case Comprehensive Cancer Center (1) · Changhai Hospital (1) · City of Hope Medical Center (1) · Emory University (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Fox Chase Cancer Center (1) · Huazhong University of Science and Technology (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (15) · China (6)
Ariela Noy, MD (1) · Brian Hill, MD (1) · Carl Allen, MD (1) · Edmund K Waller, MD, PhD (1) · Farrokh Dehdashti, M.D. (1) · Huang He, PhD (1) · Jason R. Westin, MD (1) · Jason Westin (1) · Jeffrey J. Raizer, MD (1) · Jianfeng Zhou, PhD, MD (1) · Julie M Vose, MD MBA (1) · Lode Swinnen (1) · Mark B Geyer, MD (1) · Pengcheng He, M.D. (1) · Roger Strair (1)
PMID 34435552, PMID 38143760, PMID 41633358, PMID 42490071
K12CA090433 (1), P30CA015083 (1), P30CA033572 (1), P30CA036727 (1), P30CA043703 (1), P30CA072720 (1), P30CA138292 (1), UM1CA121947 (1)